Phase II open label study of ultra-selection of patients by genotyping technology for next-generation scheme in FOLFIRI + panitumumab patients with stage IV colorectal cancer resistant to irinotecan without detectable mutations using highly sensitive techniques for the detection of mutations in genes KRAS, PIK3CA, BRAF and NRAS.

Trial Profile

Phase II open label study of ultra-selection of patients by genotyping technology for next-generation scheme in FOLFIRI + panitumumab patients with stage IV colorectal cancer resistant to irinotecan without detectable mutations using highly sensitive techniques for the detection of mutations in genes KRAS, PIK3CA, BRAF and NRAS.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms ULTRA
  • Most Recent Events

    • 12 Sep 2017 Results assessing circulating tumour DNA to track tumour heterogeneity (n=16) presented at the 42nd European Society for Medical Oncology Congress
    • 22 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 22 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top